Vaccibody aspires to provide a high service with in investor relations (‘IR’) thus seeking to support the liquidity and fair pricing of Vaccibody’s shares, and ensuring that Vaccibody is perceived as a reliable, accessible and professional company by current and potential investors and analysts.
The overarching objective of Vaccibody’s IR activities is to inform and communicate with investors, analysts and other IR stakeholders about the Company’s activities and to do so openly, honestly and in a timely fashion. We do this in compliance with relevant national statutory requirements and market regulations.
The Chief Executive Officer is responsible for the Company’s compliance with this IR policy, and reports directly to the Chairman of the Board of directors.
The Chief Executive Officer is authorised as spokesperson to communicate with capital market participants.
As a company listed on Merkur, Vaccibody publishes statements of financial results and makes other company announcements to the public in accordance with relevant statutory requirements.
The Chief Executive Officer is responsible for Vaccibody’s contact with investors and analysts, for example through regular roadshows, investor conferences, group and individual meetings, ad hoc calls and e-mail messages. We also host company updates and similar events as needed in order to further increase transparency and dialogue with investment communities. We aim at hosting a company update every year to allow investors and analysts to enhance their insights and understanding of our business.
Our communications with private shareholders primarily take place via delivery of annual reports, interim reports and company news- or announcements which are electronically distributed via Merkur.